Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2–Low Expressing Advanced Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
J. Clin. Oncol 2020 Feb 14;[EPub Ahead of Print], S Modi, H Park, RK Murthy, H Iwata, K Tamura, J Tsurutani, A Moreno-Aspitia, T Doi, Y Sagara, C Redfern, IE Krop, C Lee, Y Fujisaki, M Sugihara, L Zhang, J Shahidi, S TakahashiFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.